Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Most Popular Healthcare Stocks Under $5

Page 1 of 2

Most securities that cost less than a dinner at a fast-food restaurant are considered to be too risky, with most intra-day traders or other investors usually avoiding these low-priced stocks. While securities with price tags below $5 may be riskier, retail investors fearing these lower-priced stocks should keep in mind that Apple Inc. (NASDAQ:AAPL), Ford Motor Company (NYSE:F) and other companies once traded below the $5 price level as well. It is also true that most stocks that trade below $5 have little analyst coverage, which may enable the hedge fund industry to identify high-potential investment opportunities by leveraging their highly-skilled research teams. That’s why Insider Monkey decided to compile a list of the five most popular healthcare stocks under $5 within the hedge fund industry. Hedge fund sentiment may point to healthcare stocks that look poised to possibly trade higher from current price levels in the future, though one should not forget the risk associated with such securities.

Small Businesses in High Demand in 2015

Through extensive research, we determined that imitating some of the picks of hedge funds and other institutional investors can help generate market-beating returns over the long run. The key is to focus on the small-cap picks of these investors, since they are usually less followed by the broader market and are less price-efficient. Our backtests that covered the period between 1999 and 2012, showed that following the 15 most popular small-caps among hedge funds can help a retail investor beat the market by an average of 95 basis points per month (see more details here).

#5. QLT Inc. (USA) (NASDAQ:QLTI)

 – Investors with long positions (as of March 31): 17

 – Aggregate value of investors’ holdings (as of March 31): $39.78 Million

There were 17 hedge funds tracked by Insider Monkey with long positions in QLT Inc. (USA) (NASDAQ:QLTI) at the end of the first quarter, compared with 19 funds registered at the end of 2015. Similarly, the overall value of those positions shrank to $39.78 million from $56.88 million quarter-over-quarter. It should be noted that the 17 money managers had accumulated nearly 38% of QLT’s outstanding common stock as of March 31. The biotechnology company focused on developing innovative ocular products has seen its shares drop by 43% since the beginning of 2016. QLT does not generate revenue from product sales just yet, with its core operations currently focused on clinical development programs related to the company’s synthetic retinoid for the treatment of certain age-related and inherited retinal diseases. QLT’s research and development expenditures for the first quarter were $3.0 million, up from $2.2 million recorded a year earlier. Kevin Kotler’s Broadfin Capital owns 4.45 million shares of QLT Inc. (USA) (NASDAQ:QLTI) as of the end of the first quarter.

Follow Qlt Inc (NASDAQ:QLTI)
Trade (NASDAQ:QLTI) Now!

#4. Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)

 – Investors with long positions (as of March 31): 18

 – Aggregate value of investors’ holdings (as of March 31): $45.46 Million

The number of asset managers followed by Insider Monkey with stakes in Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) remained unchanged during the first three months of 2016 at 18. In the meantime, the dollar value those stakes declined to $45.46 million from $59.97 million during the quarter, with roughly 24% of the company’s outstanding shares being stockpiled by the 18 hedge fund vehicles from our extensive database. The clinical-stage biotechnology company that focuses on discovering drugs in the therapeutic areas of immunology, oncology and immuno-oncology has seen its market value decline by 17% thus far in 2016. The company’s ongoing clinical programs comprise fostamatinib, which is being studied in a Phase 3 clinical trial for immune thrombocytopenic purpura, a Phase 2 clinical trial for autoimmune hemolytic anemia, as well as a Phase 2 clinical trial for IgA nephropathy. James E. Flynn’s Deerfield Management had 2.40 million shares of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) in its equity portfolio at the end of March.

Follow Rigel Pharmaceuticals Inc (NASDAQ:RIGL)
Trade (NASDAQ:RIGL) Now!

The top three cheap healthcare stocks favored by top hedge funds are uncovered on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!